Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization of key oral therapies and the availability of newer oral and long-acting depot antipsychotics in the United States, such as Indivior’s Perseris, Otsuka / Lundbeck’s Rexulti, Allergan’s Vraylar, and Alkermes’s Aristada, competition in the U.S. market continues to intensify. As such, an understanding of the nuanced schizophrenia treatment landscape is essential to assess remaining opportunities for drugs in the space.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza, Latuda, Rexulti, Risperdal Consta, Vraylar, Perseris, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, typical antipsychotics, other generics.
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.